# A Pilot Study to Evaluate the PK Profile of PrimeC-ER Tablets in Healthy Adult Subjects

> **NCT05232461** · PHASE1 · COMPLETED · sponsor: **NeuroSense Therapeutics Ltd.** · enrollment: 12 (actual)

## Conditions studied

- Pharmacokinetics

## Interventions

- **DRUG:** PrimeC-ER 748 mg
- **DRUG:** Ciprofloxacin 750 MG
- **DRUG:** Celecoxib 200mg

## Key facts

- **NCT ID:** NCT05232461
- **Lead sponsor:** NeuroSense Therapeutics Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-04-08
- **Primary completion:** 2022-04-21
- **Final completion:** 2022-08-30
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2022-10-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05232461

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05232461, "A Pilot Study to Evaluate the PK Profile of PrimeC-ER Tablets in Healthy Adult Subjects". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT05232461. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*